BC
RDHL

Broadfin Capital’s Redhill Biopharma RDHL Stock Holding History

Broadfin Capital’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-252
Closed -$2.63M – 61
2016
Q4 		$2.63M Sell
252
-465
-65% -$5.57M 0.29% 56
2016
Q3 		$9.96M Sell
717
-20
-3% -$280K 0.89% 36
2016
Q2 		$8.01M Sell
737
-81
-10% -$937K 0.78% 33
2016
Q1 		$10M Sell
818
-12
-1% -$126K 0.97% 29
2015
Q4 		$10.7M Hold
830
– – 0.66% 40
2015
Q3 		$10.7M Buy
830
+446
+116% +$6.6M 0.6% 43
2015
Q2 		$6.77M Sell
384
-100
-21% -$1.59M 0.36% 61
2015
Q1 		$7.05M Buy
484
+232
+92% +$3.3M 0.55% 49
2014
Q4 		$3.35M Sell
252
-11
-4% -$114K 0.29% 64
2014
Q3 		$3.47M Hold
263
– – 0.36% 59
2014
Q2 		$4.6M Hold
263
– – 0.45% 54
2014
Q1 		$3.71M Buy
+263
New +$3.52M 0.36% 62

Other funds holding RDHL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVH
Psagot Value Holdings Tel Aviv, Israel $11M AUM 32.09% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Broadfin Capital's RDHL Position: Q1 2017 in Review

Broadfin Capital sold out of Redhill Biopharma (RDHL) in Q1 2017, closing a stake of 252 shares — an estimated $2.63M sold.

Broadfin Capital first reported a position in RDHL in Q1 2014 and held it in 12 quarters. The position peaked at $10.7M in Q3 2015. 24 funds tracked by Wall St. Rank hold RDHL as of Q1 2017.

  • Broadfin Capital reported no remaining Redhill Biopharma position as of Q1 2017 after selling out during the quarter.
  • Broadfin Capital sold 252 Redhill Biopharma shares in Q1 2017, an estimated $2.63M.
  • Broadfin Capital first reported a position in Redhill Biopharma in Q1 2014 and held it in 12 quarters.
  • Broadfin Capital's Redhill Biopharma position peaked at $10.7M in Q3 2015.
  • 24 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2017.

Based on Broadfin Capital's 13F filing for Q1 2017, filed 15 May 2017.